Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001)
Biomarker and diagnostic research for T-cell acute lymphoblastic leukemia has been reported in the published literature.
63 clinical trials registered, 25 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 7 PHASE3, 21 PHASE2, 26 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05626400](https://clinicaltrials.gov/study/NCT05626400) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 2:36 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Common questions about T-cell acute lymphoblastic leukemia
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL |
NA |
Hebei Senlang Biotechnology Inc., Ltd. |
RECRUITING |
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825) | Registry of Older Patients With Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT06316856](https://clinicaltrials.gov/study/NCT06316856) | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | PHASE1 | Beijing GoBroad Hospital | RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT06855810](https://clinicaltrials.gov/study/NCT06855810) | Newly-diagnosed Pediatric T-cell ALL Protocol | PHASE2 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
265 publications have been identified in PubMed for T-cell acute lymphoblastic leukemia. Research spans Basic Science / Preclinical (43%), Gene Therapy / Novel Therapeutics (18%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 115 | 43% |
New treatment approaches | 47 | 18% |
Research summaries | 29 | 11% |
Clinical study results | 28 | 11% |
Testing and diagnosis research | 16 | 6% |
Patient case studies | 15 | 6% |
Disease patterns and progression | 13 | 5% |
Other research | 2 | 1% |
Celona L (2026). [PMID: 42165843](https://pubmed.ncbi.nlm.nih.gov/42165843/). *Expert Rev Hematol*. [Review / Meta-Analysis]
Zhu K (2026). [PMID: 41412212](https://pubmed.ncbi.nlm.nih.gov/41412212/). *Cancer Lett*. [Diagnostic / Biomarker]
Palhais B (2026). [PMID: 41537349](https://pubmed.ncbi.nlm.nih.gov/41537349/). *Haematologica*. [Basic Science / Preclinical]
Pinton A (2026). [PMID: 41592282](https://pubmed.ncbi.nlm.nih.gov/41592282/). *Blood*. [Diagnostic / Biomarker]
Tang G (2026). [PMID: 41796805](https://pubmed.ncbi.nlm.nih.gov/41796805/). *Mod Pathol*. [Diagnostic / Biomarker]
Stanulović VS (2026). [PMID: 40637766](https://pubmed.ncbi.nlm.nih.gov/40637766/). *Haematologica*. [Basic Science / Preclinical]
He L (2026). [PMID: 41125904](https://pubmed.ncbi.nlm.nih.gov/41125904/). *Cancer Gene Ther*. [Basic Science / Preclinical]
Kim HY (2026). [PMID: 41093603](https://pubmed.ncbi.nlm.nih.gov/41093603/). *Ann Lab Med*. [Basic Science / Preclinical]
Luo Y (2026). [PMID: 41290542](https://pubmed.ncbi.nlm.nih.gov/41290542/). *Adv Sci (Weinh)*. [Gene Therapy / Novel Therapeutics]
Gao J (2026). [PMID: 41947770](https://pubmed.ncbi.nlm.nih.gov/41947770/). *Cancer Sci*. [Gene Therapy / Novel Therapeutics]